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Abstract
Background: Intravenous bisphosphonates have been used in metastatic breast cancer patients to reduce
pathologic bone fracture and bone pain. However, necrosis of the jaw has been reported in those who received
intravenous bisphosphonates. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is caused by dental
extraction, dental implant surgery, and denture wearing; however, it occurs spontaneously. The purpose of this
study was to report BRONJ in metastatic breast cancer patients.
Methods: Consecutive 25 female patients were referred from the Department of Oncology from 2008 to 2014
for jaw bone discomfort. Staging of breast cancer, history of bisphosphonate infusion, etiology of BRONJ, and
treatment results were reviewed. Average age of the patients was 55.4 years old (38–74). Twelve maxillae and 16
mandibles were involved. Conservative treatments such as irrigation, antibiotic medication, analgesics, and oral
gargle were applied for all patients for the initial treatment. Patients who had sequestrum underwent debridement
and primary closure.
Results: The etiologies of BRONJ were dental extraction (19 cases), dental implant (2 cases), and endodontic
treatment (1 case). However, three patients did not have any risk factors to cause BRONJ. Three patients died of
progression of metastasis during follow-up periods. Surgical debridement was performed in 21 patients with
success in 18 patients. Three patients showed recurred bone exposure and infection after operation.
Conclusions: Prevention of the BRONJ is critical in metastatic breast cancer patients. Conservative treatment to
reduce pain, discomfort, and infection is recommended for the initial therapy. However, if there is a sequestrum,
surgical debridement and primary closure is the key to treat the BRONJ.
Keywords: Bisphosphonate, Breast cancer, Bisphosphonate-related osteonecrosis of the jaw (BRONJ), Extraction,
Dental implant
Background
Currently, breast cancer is an increasing cause of cancer-
induced deaths in the world [1]. Multimodality treatment
strategies have been proposed for eradicating breast can-
cer, but still, many patients with breast cancer are in mul-
tiple threats to their lives [2]. The bone is the most
vulnerable site for breast cancer metastasis. Bone micro-
environment has a significant role in harboring dis-
seminated tumor cells and a source of late relapse [3].
Therefore, agents that affect bone metabolism might pro-
vide meaningful reductions in the risk of metastasis as
well as prevent the development of bone lesions [4]. Ma-
lignancy and cancer treatment-induced bone loss can
make bone mineral reserves decrease, and patients would
face risks of skeletal-related events (SREs) such as patho-
logic fracture and spinal cord compression [3].
Breast cancer cells usually metastasize to the bone by
secreting factors that enable tumor cells to be gathered
inside of the bone tissues. Tumor cells produce cytokines
that induce osteoclast formation and bone resorption such
as interleukin-8 and parathyroid hormone-related protein
[2]. Osteoclast would increase both osteolysis and the
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release of tumor-promoting growth factors from the bone
matrix. Using antiresorptive agents to cease osteolysis
should make the bone microenvironment difficult for can-
cer stem cell survival and growth [2].
In patients with bone metastases or multiple myeloma,
bisphosphonates are part of the standard treatments [2, 5].
Bisphosphonates are analogs of inorganic pyrophosphates,
commonly used for the management of metastatic bone
disease such as breast cancer, prostate cancer, and mul-
tiple myeloma. Bisphosphonates are capable of localizing
metastatic lesions and inhibiting osteoclastic function
[6–8]. Because bisphosphonates bind strongly to ex-
posed bone mineral around resorbing osteoclasts, high
levels of bisphosphonate in the resorption lacunae would
remain even after several years. Within the bone, bispho-
sphonates are not metabolized and these high concentra-
tions will be held for long periods of time [6]. Although
whole mechanism of this bisphosphonate-related osteo-
clast inhibition has not been completely explained, it has
been considered that these compounds affect bone turn-
over at various levels [9]. On a cellular level, the bispho-
sphonates target the osteoclasts and may inhibit their
function as follows: hindering the osteoclast recruitment;
reducing the osteoclast life span [10, 11]. At a molecular
level, it has been supposed that bisphosphonates regulate
osteoclastic function by interacting with a cell surface re-
ceptor or an intracellular enzyme [12]. About 300,000–
500,000 cancer patients were prescribed intravenous (IV)
bisphosphonates in 2004 [13].
The metastatic breast cancer patients who need for
bisphosphonate therapy should be relieved from the
bone pain and hypercalcemia and improve quality of life
[6]. Bisphosphonate therapy has shown dramatic effect
on reducing the risk of SREs by reducing this risk by
nearly one third, and because of this reason, intravenous
bisphosphonates are commonly used in the oncology
practice [14, 15]. Zolendronate, the most potent bisphos-
phonate, is the second-generation bisphosphonate and
approved for patients with metastatic breast cancer, mul-
tiple myeloma, hypercalcemia of malignancy, or Paget’s
disease of bone and for patients with documented bone
metastases from any solid tumor (i.e., prostate cancer,
lung cancer) [6]. In comparison with other bisphospho-
nates, zolendronate is crucially more effective in redu-
cing the risks of SREs and controlling hypercalcemia of
malignancy [16].
Bisphosphonate-related osteonecrosis of the jaw
(BRONJ), first reported by Marx in 2003, is a rare but
emerging complication associated with long-term use of
bisphosphonates, especially pamidronate and zoledro-
nate [17]. The common symptoms of BRONJ are teeth
mobility, swelling, bone dehiscence, chronic bone necro-
sis, and osteolytic radiographic features. The American
Association of Oral and Maxillofacial Surgeons (AAOMS)
proposed a staging system to suggest guidelines for prog-
nosis and treatment of BRONJ (Table 1) [18]. There are
several reports regarding breast cancer with jaw bone
necrosis [3, 19–21]; however, no case review has been re-
ported in our country. In the present study, we tried to
evaluate the BRONJ in breast cancer patients who were
treated with intravenous BPs that whether conservative or
surgical management worked on each stage.
Methods
A total of 25 female BRONJ patients who suffered from
breast cancer with bone metastasis from January 2008
to November 2014 were included in this study. All
patients had received zolendronate (Zometa®, Novatis,
USA) for treating metastatic bone lesions. Average
age was 55.4 years old (38–74). Twelve maxillae and
16 mandibles were involved. The diagnosis of BRONJ
in these patients was based on the guidelines provided by
the AAOMS position paper (Table 1) [18]. Staging of the
breast cancer, duration of bisphosphonate usage, etiology
of BRONJ, and treatment results were reviewed retro-
spectively. Conservative treatment with irrigation, anti-
biotic medication, analgesics, and oral gargle was applied
for all patients for the initial treatment. Patients who had
a sequestrum underwent debridement and primary closure.
Because of the retrospective study with de-identification of
the patient’s data, institutional review board of our institu-
tion exempted ethical review of this study.
Results
Staging and treatment of breast cancer
Staging of the breast cancer at initial visit, past treat-
ment history about surgery, chemotherapy and radiation,
Table 1 Staging of bisphosphonate-related osteonecrosis of the
jaw
Stages Description
At risk No apparent necrotic bone in patients who have been
treated with either oral or intravenous bisphosphonates.
Stage 0 There is no clinical evidence of necrotic bone, but there
are nonspecific clinical findings and symptoms such as
swelling of the soft tissue and fistula formation.
Stage 1 There is exposed and necrotic bone or fistulas that
probes to the bone in asymptomatic patients but there
is no evidence of infection.
Stage 2 There is exposed and necrotic bone or fistulas that
probes to the bone associated with infection as
evidenced by pain and erythema in the region of
exposed bone with or without purulent drainage.
Stage 3 There is exposed and necrotic bone or a fistula that
probes to the bone with pain, infection, and one or
more of the following: exposed and necrotic bone
extending beyond the region of alveolar bone resulting
in (1) pathologic fracture, (2) extraoral fistula, (3) oral-antral/
oral-nasal communication, or (4) osteolysis extending to
the inferior border of the mandible or sinus floor.
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and survival of breast cancer patients are summarized
(Table 2). The staging of breast cancer patients was
based on the guidelines provided by American Joint
Committee on Cancer (AJCC) staging manual (7th edi-
tion) [22]. Survival period means the months from oper-
ation date or the day that biopsy proved malignant
breast cancer when operation did not perform to the
latest follow-up. According to AJCC cancer staging man-
ual, two (8 %) were stage 1, eleven (44 %) were stage 2,
three (12 %) were stage 3, and nine patients (36 %) were
stage 4. Nine patients underwent chemotherapy without
surgery. The mean follow-up period was 16.0 months
(2–65 months) and mean survival period of patients was
96.2 (10–240). Three patients died of progression of
metastasis during follow-up periods.
Clinical features and medical history
Initial symptoms were pain in sixteen patients (64 %),
swelling in seven (28 %), pus discharge in eight (32 %),
tooth mobility in two (8 %), unhealed operation site in
three (12 %), intraoral fistula in one (4 %), while multiple
symptoms were observed in individuals (Table 3). Man-
dible was involved in 16 patients and maxilla in 12 pa-
tients. Three patients were affected both mandible and
maxilla. The etiologies for BRONJ were mainly tooth ex-
traction in nineteen patients (76 %), dental implant in
two (8 %), endodontic treatment in one (4 %), and spon-
taneously occurred in three patients (12 %). Based on
the BRONJ classifications of AAOMS position paper,
one patient (4 %) was stage 3, sixteen (64 %) were stage 2,
one (4 %) was stage 1, and six (24 %) were stage 0. All of
the patients had received intravenous bisphosphonate
therapy with 4 mg of zolendronate every month. Mean
number of Zometa® injection was 32.7 (3–114) times. In
the aspect of comorbidity, 3 of 25 patients were affected
by diabetes mellitus and 4 were affected by hypertension.
Treatment and outcome for BRONJ
All 25 patients were treated conservatively with antibi-
otics, chlorohexidine gargle, and analgesics at the time
Table 2 Staging, treatment, and survival of metastatic breast cancer patients
Case number Age Sex Stage Operation (Y/N) Chemotherapy (Y/N) Survival (Y/N) Survival period (months)
1 45 F IIA Y Y Y 118
2 53 F IV N Y Y 36
3 58 F IC Y N Y 105
4 55 F IIB Y Y Y 76
5 70 F IIA Y Y Y 240
6 59 F IIB Y Y Y 39
7 67 F IV N Y Y 104
8 50 F IIA Y N Y 139
9 61 F IV N Y N 42
10 51 F IIIA Y Y Y 149
11 55 F IV N Y Y 44
12 52 F IV N Y Y 64
13 67 F IIIA Y Y Y 93
14 38 F IIIC Y Y N 132
15 65 F IIB Y Y Y 175
16 49 F IV N Y N 19
17 49 F IIB Y Y Y 124
18 48 F IIA Y Y Y 135
19 70 F IIA Y Y Y 150
20 42 F IV N Y Y 10
21 49 F IIA Y Y Y 94
22 48 F IIA Y Y Y 124
23 55 F IV N Y Y 23
24 54 F IV N Y Y 86
25 74 F IA Y Y Y 85
F female, survival period means the months from operation date or the day that biopsy proved malignant breast cancer when operation did not perform to the
last follow-up
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of initial visit. Surgical treatment was performed in 21
patients (Table 4). Most of the patients required seques-
trectomy and saucerization. Two patients underwent
simple curettage and one underwent dental implant fix-
ture removal. Four patients (16 %) were managed by
conservative treatment solely. When BRONJ was diag-
nosed, patient had been recommended to stop adminis-
tration of zolendronate except one who suffered from
bone metastasis on mandible (No. 12 patient). Systemic
condition and intraoral and extraoral characteristics
were assessed in collaboration with medical oncologists.
A surgical approach was considered after 3 months of
bisphosphonate discontinuation in patients with chronic
symptoms. In this study, surgical treatment was per-
formed in 21 patients (84 %) with success in 18 patients.
Three patients showed repeated bone exposure and in-
fection after initial operation. Healing of the oral mucosa
was observed in 19 patients (76 %) with no other signs.
Case review
In September 2014, number 2 patient was referred from
the Department of Oncology for maxillary bone pain
and gingival swelling after extraction of the right maxil-
lary premolar. Her stage of breast cancer was IV, and
Table 3 Clinical features and bisphosphonate history of patients
Case
number
Age Sex Chief complaint Location Trigger event Stage BP therapy Dose Injection times Comorbid disease
1 45 F Itching sensation Maxilla Extraction 1 Zolendronate 4 mg/monthly 44 -
2 53 F Pain, swelling Maxilla Extraction 2 Zolendronate 4 mg/monthly 41 Hypertension
3 58 F Pain, Swelling Mandible Endo 2 Zolendronate 4 mg/monthly 3 -
4 55 F Swelling, unhealing
extraction socket
Mandible Extraction 0 Zolendronate 4 mg/monthly 7 -
5 70 F Pain, swelling,
pus discharge
Mandible Implant 2 Zolendronate 4 mg/monthly 18 Diabetes mellitus,
hypertension
6 59 F Pain, pus discharge Maxilla Extraction 2 Zolendronate 4 mg/monthly 20 Hypertension
7 67 F Pain, pus discharge Maxilla Extraction 0 Zolendronate 4 mg/monthly 24 Hypertension
8 50 F Pus discharge,
unhealing
implantation site
Mandible Implant 0 Zolendronate 4 mg/monthly 114 -
9 61 F Pain, swelling,
pathologic fracture
Mandible Extraction 3 Zolendronate 4 mg/monthly 7 Diabetes mellitus
10 51 F Pain Maxilla Extraction 2 Zolendronate 4 mg/monthly 49 Diabetes mellitus
11 55 F Pain Mandible Extraction 2 Zolendronate 4 mg/monthly 14 -
12 52 F Tooth mobility Mandible Extraction 0 Zolendronate 4 mg/monthly 67 -
13 67 F Pain, tooth mobility Bilateral
mandible
Extraction 2 Zolendronate 4 mg/monthly 20 -
14 38 F Pus discharge Maxilla Extraction 2 Zolendronate 4 mg/monthly 21 -
15 65 F Pus discharge Maxilla Extraction 2 Zolendronate 4 mg/monthly 23 -
16 49 F Pus discharge Mandible Extraction 0 Zolendronate 4 mg/monthly 13 Hypothyroidism
17 49 F Pain Mandible Extraction 2 Zolendronate 4 mg/monthly 58 -
18 48 F Pain, swelling Maxilla and
mandible
Extraction 2 Zolendronate 4 mg/monthly 47 -




Extraction 2 Zolendronate 4 mg/monthly 52 -
20 42 F Pus discharge Maxilla and
mandible
Extraction 2 Zolendronate 4 mg/monthly 40 -
21 49 F Pain Maxilla Spontaneous 0 Zolendronate 4 mg/monthly 9 -
22 48 F Pain, pus discharge Mandible Extraction 2 Zolendronate 4 mg/monthly 43 -
23 55 F Pain Mandible Spontaneous 2 Zolendronate 4 mg/monthly 10 -
24 54 F Pain Maxilla Extraction 2 Zolendronate 4 mg/monthly 48 -
25 74 F Swelling,
intraoral fistula
Mandible Spontaneous 2 Zolendronate 4 mg/monthly 25 -
F female
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she had received chemotherapy for palliative treatment.
She had received intravenous bisphosphonate for more
than 3 years and had hypertension for comorbidity. Nec-
rotic bone was observed on the buccal side of right upper
premolars. After a month of conservative therapy, she
underwent sequestrectomy and primary closure with buc-
cal fat graft. Inflamed mucosa and necrotic sequestrum
had been treated and all of the clinical symptoms were
improved (Fig. 1a–d).
Number 12 patient was referred from the Department
of Oncology complaining of tooth mobility during
chemotherapy. Her stage of breast cancer was also IV,
and she did not undergo operation because of multiple
bone metastases. She had received chemotherapy for
palliative treatment. She had received intravenous bis-
phosphonates for more than 5 years. According to the
bone scan image, hot uptake was found in the anterior
mandible which resembled bone metastasis. For differ-
ential diagnosis, biopsy was performed before operation
resulting in osteomyelitis with bacterial contamination.
During conservative treatment, she reported skin fistula
and necrotic bone exposure in oral cavity. Due to fast
progression of the metastasis, no surgical exploration
was performed (Fig. 2a–d).
Number 22 patient was referred from the Department
of Oncology for mandible bone pain and pus discharge
on the left lower molar area where extraction had been
performed in previous dental clinic. Her stage of breast
cancer was IIA, and she underwent operation. She had
been treated with intravenous bisphosphonate for more
than 3 years after realizing bone metastasis. Sequestrum
was observed on panoramic view. For surgical debride-
ment, bisphosphonate was discontinued for 2 months
before operation. After surgery, progression of BRONJ
ceased without pain and swelling. Two months post-
operation, cortical margin around operation site was
distinct in panoramic view (Fig. 3a–d).
Discussion
It has been reported that the incidence of BRONJ with
intravenous bisphosphonates is more frequent than that
with oral bisphosphonates [23]. The incidence of BRONJ
Table 4 Treatment and outcome of patients
Case number Age Sex Surgical treatment Follow-up (M) BP discontinuation Outcome
1 45 F Sequestrectomy 19 Yes Healed mucosa
2 53 F Sequestrectomy 5 Yes Healed mucosa
3 58 F Sequestrectomy 12 Yes Another bony exposure (Mx), death
4 55 F Conservative management 12 Yes Healed mucosa
5 70 F Sequestrectomy 65 Yes Healed mucosa
6 59 F Conservative management 2 Yes No more follow-up with unhealed state
7 67 F Curettage 12 Yes Healed mucosa
8 50 F Implant removal 17 Yes Bony exposure
9 61 F Segmental mandibulectomy 36 Yes Death
10 51 F Sequestrectomy 18 Yes Healed mucosa
11 55 F Sequestrectomy 25 Yes Healed mucosa
12 52 F Conservative management 19 No Mandible metastasis, skin fistula
13 67 F Sequestrectomy 11 Yes Healed mucosa
14 38 F Sequestrectomy 6 Yes Healed mucosa, death
15 65 F Sequestrectomy 9 Yes Healed mucosa
16 49 F Curettage 2 Yes No more follow-up with healed state
17 49 F Sequestrectomy 35 Yes Healed mucosa and skin
18 48 F Sequestrectomy 6 Yes Bony exposure
19 70 F Sequestrectomy 21 Yes Healed mucosa
20 42 F Sequestrectomy 10 Yes Healed mucosa
21 49 F Conservative management 10 Yes Healed mucosa
22 48 F Sequestrectomy 4 Yes Healed mucosa
23 55 F Sequestrectomy 13 Yes Healed mucosa
24 54 F Sequestrectomy 17 Yes Healed mucosa
25 74 F Sequestrectomy 14 Yes Healed mucosa
F female, BP bisphosphonate, M month, Mx maxilla
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with intravenous bisphosphonates has been reported
0.8–1.2 % on average, increasing up to 21 % after injec-
tion of bisphosphonate for 3 years or more [5, 24, 25].
Bisphosphonates bind to bone hydroxyapatite for almost
10 years, and because of this reason, discontinuation of
bisphosphonate administration before dental treatment
is still disputable [26]. Cancer patients who have high
risks for bone pain, hypercalcemia, or pathological fracture
could effectively benefit from intravenous bisphospho-
nates. However, BRONJ could happen during treatment
[3, 19–21]. When BRONJ is suspicious, it is highly recom-
mended to stop using them. In this study, 24 patients
stopped taking bisphosphonates after consulting with an
oncologist. However, it could not be discontinued in one
patient who had suffered from multiple bone metastases
with hypercalcemia.
The relatively high percentage of the maxilla (12 of 25
patients) involvement of BRONJ in this study is uncom-
mon because the maxilla is provided with rich vascular
supply. This finding is distinguished from other studies
Fig. 1 Clinical, panoramic examinations of patient (No. 2 patient). a Exposed maxillary bone in the buccal side of second premolar. b Initial
panoramic view showing bone destruction in the right maxillary premolar area with unhealed extraction socket. c Intraoral photograph showing
healed mucosa 4 months postoperation. d Panoramic view showing bone defect in right maxillary premolar area 4 months postoperation
Fig. 2 Clinical, panoramic, and bone scan examinations of patient (No. 12 patient). a Clinical photograph of exposed mandible. b Panoramic
image during conservative treatment. c Extraoral fistula formation with pus discharge in the right submental area. d Bone scan image showing
hot uptake in the anterior mandible
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which reported dominant involvement of the mandible
[27–30]. It may be related to the mechanism by which
bisphosphonates would not only inhibit the angiogenesis
but also affect in other way [18]. One of the most
frequent initiations of BRONJ is a dental extraction. In
our case series, dental extraction was more frequent in
the maxilla than the mandible.
The potent inhibition of osteoclast proceeds to reduce
bone resorption and interrupt normal bone turnover
remodeling, resulting in reduction of some mechanical
properties in skeletal health [31]. As bone resorption
occurs, cytokines and growth factors would be released
into the surrounding matrixes that are significant for
regulating new bone development. The inhibition of new
bone formation would lead to degrade bone quality dur-
ing growth and fracture healing [6]. Systemic conditions
of patients involving diabetes mellitus or coagulopathy
have also been reported as a risk factor for BRONJ
[18, 32]. In the present study, three of the patients
had diabetes mellitus.
Bisphosphonate therapy should be delayed until all ne-
cessary dental treatments have been performed, except
life-threatening hypercalcemia [18]. In this report, dental
extraction was the most common etiology for BRONJ
initiation. Other surgical procedures such as dental im-
plant surgery and preprosthetic surgical treatment could
be the causes of BRONJ [33]. During bisphosphonate
therapy, patients should manage their oral hygiene. Inva-
sive dental procedures should be avoided during bisphos-
phonate therapy, if that is possible. Bacterial infection was
observed in all the present cases, therefore, antibiotic
treatment should be ensured on BRONJ patients [23].
Recent studies have reported that surgical debride-
ment might have benefited in eradicating necrotic bone
in comparison with conservative treatment [27, 34–36].
If invasive dental procedure is determined, a systemic
perioperative antibiotic treatment is recommended. Sur-
gical debridement should be done for those patients
who complained symptoms. Obtaining a surgical margin
with viable bleeding the bone is significant in surgery,
and primary closure for wound healing should be served
by using mucosal flaps for bone coverage [3]. It is rec-
ommended that bisphosphonate administration should
be withheld for 6–8 weeks before and after dental proce-
dures [3, 18]. After complete wound healing is achieved,
bisphosphonate therapy could be reinitiated because the
risk of SREs would still exist and increase during the
course of disease [37]. Despite the several efforts for
setting guidelines, the optimum treatment for BRONJ
remains unclarified. It is necessary to accumulate further
clinical data to make the standard for effective treatment
in BRONJ patients.
Conclusions
Prevention of the BRONJ is critical in metastatic
breast cancer patients. Dental extraction is the main
etiology for BRONJ. Conservative treatment to reduce
pain, discomfort, and infection is recommended for
the initial therapy. However, if there is a sequestrum
which is separated from the basal bone of the jaw,
Fig. 3 Clinical, panoramic examinations of patient (No. 22 patient). a Intraoral photograph showing inflamed mucosa with swelling. b Panoramic
view showing sequestrum in the left posterior mandible. c Intraoral photograph showing healed mucosa 2 months postoperation. d Panoramic
view showing cortical bone healing and resection of sequestrum 2 months postoperation
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surgical debridement and primary closure is the key
to treat the BRONJ.
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